CHF6001 matching placebo, CHF6001 DPI clinical trials

A 52-week, randomised, double blind, multicentre, 2-arm parallel group trial assessing the efficacy and safety of CHF6001 (total daily dose 3200 μg) Dry Powder Inhaler (DPI) add-on to maintenance medium or high dose inhaled corticosteroid in combination with long-acting ß2-agonists in subjects with uncontrolled asthma

This study looks at a new inhaler, CHF6001, for people with asthma that isn't fully controlled. Researchers want to see if adding this new inhaler to their usual medication helps reduce asthma attacks over 52 weeks and is safe.